Identification

Name
Capsaicin
Accession Number
DB06774  (DB05674, DB05318)
Type
Small Molecule
Groups
Approved
Description

Capsaicin is most often used as a topical analgesic and exists in many formulations of cream, liquid, and patch preparations of various strengths; however, it may also be found in some dietary supplements. Capsaicin is a naturally-occurring botanical irritant in chili peppers, synthetically derived for pharmaceutical formulations. The most recent capsaicin FDA approval was Qutenza, an 8% capsaicin patch dermal-delivery system, indicated for neuropathic pain associated with post-herpetic neuralgia.

Structure
Thumb
Synonyms
  • (E)-8-Methyl-N-vanillyl-6-nonenamide
  • Isodecenoic acid vanillylamide
  • trans-8-Methyl-N-vanillyl-6-nonenamide
External IDs
ALGRX 4975 / ALGRX-4975 / FEMA NO. 3404 / NGX-1998 / NGX-4010 / NSC-56353
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
QutenzaKitNeuroges X2010-03-01Not applicableUs
QutenzaPatch179 mgCutaneousGrunenthal Gmb H2009-05-15Not applicableEu
QutenzaKitAcorda Therapeutics2013-08-12Not applicableUs
QutenzaPatch179 mgCutaneousGrunenthal Gmb H2009-05-15Not applicableEu
QutenzaKitAcorda Therapeutics2013-08-12Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
2-Count HEAT PATCHESPatch.025 g/100gTopicalChain Drug Consortium2017-06-01Not applicableUs
2-Count HEAT PATCHESPatch.025 g/100gTopicalQuality Choice (Chain Drug Marketing Association, Inc.)2017-06-01Not applicableUs
2-Count HEAT PATCHESPatch.025 g/100gTopicalDiscount Drug Mart, Inc2017-06-01Not applicableUs
2-Count HEAT PATCHESPatch4 g/100gTopicalVeridian Healthcare2017-06-01Not applicableUs
Ageranium PatchPatch.228 mg/99.13mgTopicalEntom Co., Ltd.2017-12-29Not applicableUs
Antiphlogistine Rub A-535 Capsaicin GelGel0.05 %TopicalChurch & Dwight Company, Inc.1998-11-232007-07-23Canada
Antiphlogistine Rub A-535 Capsaicin LiquidLiquid0.025 %TopicalCarter Horner Corp.1998-11-232001-07-18Canada
Arthricare for Women Extra MoisturizingLotion0.025 %TopicalDel Pharmaceuticals Inc.2000-08-082005-06-20Canada
Arthricare for Women Quick DryingCream0.025 %TopicalDel Pharmaceuticals Inc.2002-06-172005-06-20Canada
Arthritazin Pain RelievingGel.06375 g/255gTopicalConcept Laboratories2013-01-172017-10-21Us
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Aflexeryl-MCCapsaicin (.0375 g/100g) + Menthol (5 g/100g)PatchTopicalEasy Distributors, Llc2015-01-142016-10-13Us
Alegenix Biofrequency ChipCapsaicin (.0375 g/100g) + Menthol (5 g/100g)DiscTopicalSolubiomix2015-06-012030-01-01Us
AlivioCapsaicin (.05 g/100g) + Menthol (4 g/100g)PatchTopicalAble Wholesalers2014-12-302017-01-20Us
AlivioCapsaicin (2.4 mg/8g) + Menthol (400 mg/8g)PatchTopicalZhejiang Bangli Medical Products Co., Ltd2015-01-152016-11-01Us
AlivioCapsaicin (.03 g/100g) + Menthol (5 g/100g)PatchTopicalZhejiang Bangli Medical Products Co., Ltd2015-01-152016-10-13Us
Alivio Medicated PainCapsaicin (.03 g/100g) + Menthol (5 g/100g)PatchTopicalAlivio Medical Products, Llc2015-01-212017-11-04Us
AllevessCapsaicin (.05 g/100g) + Menthol (5 g/100g)PatchTopicalApi Solutions, Inc.2015-12-01Not applicableUs
Ameri PatchCapsaicin (.0375 g/100g) + Menthol (5 g/100g)PatchTopicalZhejiang Bangli Medical Products Co., Ltd2015-03-152016-10-13Us
AmeriPatchCapsaicin (.0375 g/100g) + Menthol (5 g/100g)PatchTopicalMeds Direct Rx, Inc.2015-01-31Not applicableUs
Apanol Linimento ObreroCapsaicin (10 g/100g) + Methyl salicylate (27 g/100g)OintmentTopicalDelon Laboratories (1990) Ltd.2010-11-072016-10-13Us
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
1st Medxpatch With Lidocaine 4%Capsaicin (.0375 1/1) + Lidocaine (4 1/1) + Menthol (5 1/1) + Methyl salicylate (20 1/1)PatchTopical1 St Medx Llc2018-03-15Not applicableUs
1st Medxpatch With Lidocaine 4%-rxCapsaicin (.0375 1/1) + Lidocaine (4 1/1) + Menthol (5 1/1) + Methyl salicylate (20 1/1)PatchTopical1 St Medx Llc2018-03-15Not applicableUs
AdazinCapsaicin (.035 g/100g) + Benzocaine (2 g/100g) + Lidocaine (2 g/100g) + Methyl salicylate (1 g/100g)CreamTopicalSterling Knight Pharmaceuticals, Llc2014-12-03Not applicableUs
AnodyneRxCapsaicin (.05 g/1) + Lidocaine (2.5 g/1) + Menthol (5 g/1)PatchTopicalGen Pak Solutions, Llc2015-04-012016-10-13Us
BioachesCapsaicin (.0375 g/1) + Menthol (5 g/1)PatchTopicalBio Santee Chem2015-01-10Not applicableUs
CapmentCapsaicin (0.0375 1/100g) + Menthol (5 1/100g)PatchTopicalOriginal Patch Company Inc2015-03-312017-09-05Us
CapmentCapsaicin (0.0375 g/100g) + Menthol (5 g/100g)PatchTopicalOriginal Patch Company Inc2015-03-24Not applicableUs
CapxibCapsaicin + Celecoxib + MentholKitOral; TopicalMas Management Group2015-06-032018-04-11Us
Dolor-parche With Lidocaine-RXCapsaicin (.035 g/1) + Lidocaine (.5 g/1) + Menthol (5 g/1) + Methyl salicylate (20 g/1)PatchTopicalTwo Hip Consulting, Llc2013-07-312016-10-13Us
Doloracin RxCapsaicin (.035 g/100mL) + Menthol (5 g/100mL) + Methyl salicylate (20 g/100mL)CreamTopicalTwo Hip Consulting, Llc2013-08-112016-10-13Us
Categories
UNII
S07O44R1ZM
CAS number
404-86-4
Weight
Average: 305.4119
Monoisotopic: 305.199093735
Chemical Formula
C18H27NO3
InChI Key
YKPUWZUDDOIDPM-SOFGYWHQSA-N
InChI
InChI=1S/C18H27NO3/c1-14(2)8-6-4-5-7-9-18(21)19-13-15-10-11-16(20)17(12-15)22-3/h6,8,10-12,14,20H,4-5,7,9,13H2,1-3H3,(H,19,21)/b8-6+
IUPAC Name
(6E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide
SMILES
COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1

Pharmacology

Indication

The capsaicin 8% patch is indicated in the treatment of neuropathic pain associated with post-herpetic neuralgia. There are multiple topical capsaicin formulations available, including creams and solutions, indicated for temporary analgesia in muscle and join pain as well as neuropathic pain.

Associated Conditions
Pharmacodynamics

Capsaicin is a TRPV1 receptor agonist. TRPV1 is a trans-membrane receptor-ion channel complex activated by temperatures higher than 43 degrees Celsius, pH lower than 6, and endogenous lipids. When activated by a combination of these factors, the channel can transiently open and initiate depolarization due to the influx of calcium and sodium ions. Because TRPV1 is commonly expressed in A-delta and mostly C fibers, depolarization results in action potentials which send impulses to the brain and spinal cord. These impulses result in capsaicin effects of warming, tingling, itching, stinging, or burning. Capsaicin also causes more persistent activation of these receptors compared to the environmental agonists, resulting in a loss of response to many sensory stimuli, described as "defunctionalization". Capsaicin is associated with many enzymatic, cytoskeletal, and osmotic changes, as well as disruption of mitochondrial respiration, impairing nociceptor function for extended periods of time.

Mechanism of action

Capsaicin has been shown to reduce the amount of substance P associated with inflammation - however this is not believed to be its main mechanism in the relief of pain [4]. Capsaicin's mechanism of action is attributed to "defunctionalization" of nociceptor fibers by inducing a topical hypersensitivity reaction on the skin. This alteration in pain mechanisms is due to many of the following: temporary loss of membrane potential, inability to transport neurotrophic factors leading to altered phenotype, and reversible retraction of epidermal and dermal nerve fiber terminals.

TargetActionsOrganism
ATransient receptor potential cation channel subfamily V member 1
agonist
Human
UProhibitin-2Not AvailableHuman
Absorption

Oral: Following oral administration, capsaicin may be absorbed by a nonactive process from the stomach and whole intestine with an extent of absorption ranging between 50 and 90%, depending on the animal [4]. The peak blood concentration can be reached within 1 hour following administration [4]. Capsaicin may undergo minor metabolism in the small intestine epithelial cells post-absorption from the stomach into the small intestines. While oral pharmacokinetics information in humans is limited, ingestion of equipotent dose of 26.6 mg of pure capsaicin, capsaicin was detected in the plasma after 10 minutes and the peak plasma concentration of 2.47 ± 0.13 ng/ml was reached at 47.1 ± 2.0 minutes [4].

Systemic: Following intravenous or subcutaneous administration in animals, the concentrations in the brain and spinal cord were approximately 5-fold higher than that in blood and the concentration in the liver was approximately 3-fold higher than that in blood [4].

Topical: Topical capsaicin in humans is rapidly and well absorbed through the skin, however systemic absorption following topical or transdermal administration is unlikely [4]. For patients receiving the topical patch containing 179 mg of capsaicin, a population analysis was performed and plasma concentrations of capsaicin were fitted using a one-compartment model with first-order absorption and linear elimination. The mean peak plasma concentration was 1.86 ng/mL but the maximum value observed in any patient was 17.8 ng/mL [4].

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Capsaicin metabolism after oral administration is unclear, however it is expected to undergo metabolism in the liver with minimal metabolism in the gut lumen. In vitro studies with human hepatic microsomes and S9 fragments indicate that capsaicin is rapidly metabolized, producing three major metabolites, 16-hydroxycapsaicin, 17-hydroxycapsaicin, and 16,17-hydroxycapsaicin, whereas vanillin was a minor metabolite [4]. It is proposed that cytochrome P450 (P450) enzymes may play some role in hepatic drug metabolism [4]. In vitro studies of capsaicin in human skin suggest slow biotransformation with most capsaicin remaining unchanged.

Route of elimination

It is proposed that capsaicin mainly undergoes renal excretion, as both the unchanged and glucuronide form. A small fraction of unchanged compound is excreted in the feces and urine. In vivo animal studies demonstrates that less than 10 % of an administered dose was found in faces after 48 h [4].

Half life

Following oral ingestion of equipotent dose of 26.6 mg of pure capsaicin, the half life was approximately 24.9 ± 5.0 min [4]. Following topical application of 3% solution of capsaicin, the half-life of capsaicin was approximately 24 h [4]. The mean population elimination half-life was 1.64 h following application of a topical patch containing 179 mg of capsaicin [4].

Clearance
Not Available
Toxicity

Acute oral LD50 and dermal LD50 in mouse are 47.2 mg/kg and >512 mg/kg, respectively [MSDS]. Capsaicin is shown to be mutagenic for bacteria and yeast [MSDS].

Capsaicin can cause serious irritation, conjunctivitis and lacrimation via contact with eyes. It induces a burning sensation and pain in case of contact with eyes and skin. As it is also irritating to the respiratory system, it causes lung irritation and coughing as well as bronchoconstriction. Other respiratory effects include laryngospasm, swelling of the larynx and lungs, chemical pneumonitis,respiratory arrest and central nervous system effects such as convulsions and excitement [5]. In case of ingestion, gastrointestinal tract irritation may be observed along with a sensation of warmth or painful burning [MSDS]. Symptoms of systemic toxicity include disorientation, fear, loss of body motor control including diminished hand-eye coordination, hyperventilation, tachycardia, and pulmonary oedema [5]. Careful early decontamination is recommended and medical intervention should be initiated for any life-threatening symptoms. In case of contact, individual must be removed from the source of exposure and the contacted skin and mucous membranes should be thoroughly washed with copious amounts of water [5].

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Capsaicin.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Capsaicin.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Capsaicin.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Capsaicin.Experimental, Illicit
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Capsaicin.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Capsaicin.Approved, Experimental, Investigational
AcenocoumarolCapsaicin may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Capsaicin.Approved
AlaproclateAlaproclate may increase the antiplatelet activities of Capsaicin.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Capsaicin.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Capsaicin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Capsaicin.Experimental, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Capsaicin.Experimental
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Capsaicin.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Capsaicin.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Capsaicin.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Capsaicin.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Capsaicin.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Capsaicin.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Capsaicin.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Capsaicin.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Capsaicin.Approved, Investigational
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Capsaicin.Approved, Investigational, Withdrawn
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Capsaicin.Investigational
AtorvastatinThe risk or severity of adverse effects can be increased when Capsaicin is combined with Atorvastatin.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Capsaicin.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Capsaicin.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Capsaicin.Approved, Investigational
BazedoxifeneCapsaicin may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Capsaicin.Experimental
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Capsaicin.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Capsaicin.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Capsaicin.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Capsaicin.Approved, Vet Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Capsaicin.Experimental
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Capsaicin.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Capsaicin.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Capsaicin.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Capsaicin.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Capsaicin.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Capsaicin.Experimental
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Capsaicin.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Capsaicin.Experimental, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Capsaicin.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Capsaicin.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Capsaicin.Approved, Investigational
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Capsaicin.Approved, Withdrawn
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Capsaicin.Approved, Investigational, Vet Approved
ChlorotrianiseneCapsaicin may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Capsaicin.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Capsaicin.Approved, Investigational
CitalopramCitalopram may increase the antiplatelet activities of Capsaicin.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Capsaicin.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Capsaicin.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Capsaicin.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Capsaicin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Capsaicin.Approved
ClorindioneCapsaicin may increase the anticoagulant activities of Clorindione.Experimental
Conjugated estrogensCapsaicin may increase the thrombogenic activities of Conjugated estrogens.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Capsaicin.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Capsaicin.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Capsaicin.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Capsaicin.Approved, Investigational
Cyproterone acetateThe serum concentration of Capsaicin can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DaidzeinCapsaicin may increase the thrombogenic activities of Daidzein.Experimental
DapoxetineDapoxetine may increase the antiplatelet activities of Capsaicin.Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Capsaicin.Approved, Investigational
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Capsaicin.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Capsaicin.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Capsaicin.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Capsaicin.Experimental, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Capsaicin.Vet Approved
DicoumarolCapsaicin may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolCapsaicin may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DiethylstilbestrolCapsaicin may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Capsaicin.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Capsaicin.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Capsaicin.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Capsaicin.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Capsaicin.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Capsaicin.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Capsaicin.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Capsaicin.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Capsaicin.Approved, Investigational
DiphenadioneCapsaicin may increase the anticoagulant activities of Diphenadione.Experimental
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Capsaicin.Withdrawn
DuloxetineDuloxetine may increase the antiplatelet activities of Capsaicin.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Capsaicin.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Capsaicin.Investigational
EpimestrolCapsaicin may increase the thrombogenic activities of Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Capsaicin.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Capsaicin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Capsaicin.Approved
EquolCapsaicin may increase the thrombogenic activities of Equol.Investigational
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Capsaicin.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Capsaicin.Approved
EscitalopramEscitalopram may increase the antiplatelet activities of Capsaicin.Approved, Investigational
Estradiol acetateCapsaicin may increase the thrombogenic activities of Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateCapsaicin may increase the thrombogenic activities of Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateCapsaicin may increase the thrombogenic activities of Estradiol valerate.Approved, Investigational, Vet Approved
EstriolCapsaicin may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedCapsaicin may increase the thrombogenic activities of Estrogens, esterified.Approved
EstroneCapsaicin may increase the thrombogenic activities of Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Capsaicin.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Capsaicin.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Capsaicin.Experimental
Ethyl biscoumacetateCapsaicin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Capsaicin.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Capsaicin.Approved, Investigational
EtoperidoneEtoperidone may increase the antiplatelet activities of Capsaicin.Withdrawn
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Capsaicin.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Capsaicin.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Capsaicin.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Capsaicin.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Capsaicin.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Capsaicin.Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Capsaicin.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Capsaicin.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Capsaicin.Experimental
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Capsaicin.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with Capsaicin.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Capsaicin.Approved, Investigational
FluindioneCapsaicin may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Capsaicin.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Capsaicin.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Capsaicin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Capsaicin.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Capsaicin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Capsaicin.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Capsaicin.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Capsaicin.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Capsaicin.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Capsaicin.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Capsaicin.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Capsaicin.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Fluticasone is combined with Capsaicin.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Capsaicin.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Capsaicin.Approved, Investigational, Withdrawn
GenisteinCapsaicin may increase the thrombogenic activities of Genistein.Investigational
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Capsaicin.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Capsaicin.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Capsaicin.Investigational
HexestrolCapsaicin may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Capsaicin.Investigational
HyaluronidaseThe risk or severity of adverse effects can be increased when Hyaluronidase is combined with Capsaicin.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Capsaicin.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Capsaicin.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Capsaicin.Approved, Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Capsaicin.Experimental
IndalpineIndalpine may increase the antiplatelet activities of Capsaicin.Investigational, Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Capsaicin.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Capsaicin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Capsaicin.Withdrawn
IsoniazidThe metabolism of Capsaicin can be decreased when combined with Isoniazid.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Capsaicin.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Capsaicin.Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Capsaicin.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Capsaicin.Approved, Vet Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Capsaicin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Capsaicin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Capsaicin.Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Capsaicin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Capsaicin.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Capsaicin.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Capsaicin.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Capsaicin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Capsaicin.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Capsaicin.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Capsaicin.Illicit, Investigational, Withdrawn
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Capsaicin.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Capsaicin.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Capsaicin.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Capsaicin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Capsaicin.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Capsaicin.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Capsaicin.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Capsaicin.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Capsaicin.Approved
MestranolCapsaicin may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Capsaicin.Approved, Investigational, Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Capsaicin.Experimental
MethallenestrilCapsaicin may increase the thrombogenic activities of Methallenestril.Experimental
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Capsaicin.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Capsaicin.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Capsaicin.Experimental
MilnacipranMilnacipran may increase the antiplatelet activities of Capsaicin.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Capsaicin.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Capsaicin.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Capsaicin.Approved, Vet Approved
MoxestrolCapsaicin may increase the thrombogenic activities of Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Capsaicin.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Capsaicin.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Capsaicin.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Capsaicin.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Capsaicin.Approved
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Capsaicin.Investigational
NefazodoneNefazodone may increase the antiplatelet activities of Capsaicin.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Capsaicin.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Capsaicin.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Capsaicin.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Capsaicin.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Capsaicin.Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Capsaicin.Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Capsaicin.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Capsaicin.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Capsaicin.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Capsaicin.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Capsaicin.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Capsaicin.Experimental, Nutraceutical
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Capsaicin.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Capsaicin.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Capsaicin.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Capsaicin.Approved, Investigational, Vet Approved, Withdrawn
PhenindioneCapsaicin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonCapsaicin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Capsaicin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Capsaicin.Approved, Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Capsaicin.Approved, Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Capsaicin.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Capsaicin.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Capsaicin.Approved
Polyestradiol phosphateCapsaicin may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Capsaicin.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Capsaicin.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Capsaicin.Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Capsaicin.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Capsaicin.Approved, Investigational
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Capsaicin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Capsaicin.Approved, Experimental, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Capsaicin.Experimental
PromestrieneCapsaicin may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Capsaicin.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Capsaicin.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Capsaicin.Experimental
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Capsaicin.Investigational
QuinestrolCapsaicin may increase the thrombogenic activities of Quinestrol.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Capsaicin.Approved, Experimental, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Capsaicin.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Capsaicin.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Capsaicin.Approved, Investigational, Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Capsaicin.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Capsaicin.Approved
SecoisolariciresinolCapsaicin may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Capsaicin.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Capsaicin.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Capsaicin.Investigational
SertralineSertraline may increase the antiplatelet activities of Capsaicin.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Capsaicin.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Capsaicin.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Capsaicin.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Capsaicin.Experimental
Synthetic Conjugated Estrogens, ACapsaicin may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BCapsaicin may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Capsaicin.Investigational
Technetium Tc-99m tilmanoceptCapsaicin may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.Approved, Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Capsaicin.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Capsaicin.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Capsaicin.Vet Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Capsaicin.Experimental
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Capsaicin.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Capsaicin.Approved
TiboloneCapsaicin may increase the thrombogenic activities of Tibolone.Approved, Investigational
TiclopidineThe metabolism of Capsaicin can be decreased when combined with Ticlopidine.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Capsaicin.Investigational
TioclomarolCapsaicin may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Capsaicin.Approved, Withdrawn
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Capsaicin.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Capsaicin.Approved
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Capsaicin.Approved, Vet Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Capsaicin.Experimental
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Capsaicin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Capsaicin.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Capsaicin.Approved, Investigational, Withdrawn
WarfarinCapsaicin may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Capsaicin.Approved, Investigational
ZeranolCapsaicin may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Capsaicin.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Capsaicin.Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Capsaicin.Withdrawn
Food Interactions
No interactions found.

References

General References
  1. Anand P, Bley K: Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth. 2011 Oct;107(4):490-502. doi: 10.1093/bja/aer260. Epub 2011 Aug 17. [PubMed:21852280]
  2. Wallace M, Pappagallo M: Qutenza(R): a capsaicin 8% patch for the management of postherpetic neuralgia. Expert Rev Neurother. 2011 Jan;11(1):15-27. doi: 10.1586/ern.10.182. [PubMed:21158551]
  3. Simpson DM, Estanislao L, Brown SJ, Sampson J: An open-label pilot study of high-concentration capsaicin patch in painful HIV neuropathy. J Pain Symptom Manage. 2008 Mar;35(3):299-306. Epub 2007 Oct 23. [PubMed:17959343]
  4. O'Neill J, Brock C, Olesen AE, Andresen T, Nilsson M, Dickenson AH: Unravelling the mystery of capsaicin: a tool to understand and treat pain. Pharmacol Rev. 2012 Oct;64(4):939-71. doi: 10.1124/pr.112.006163. [PubMed:23023032]
  5. Oleoresin Capsicum Toxicology Evaluation and Hazard Review [Link]
External Links
Human Metabolome Database
HMDB0002227
KEGG Drug
D00250
KEGG Compound
C06866
PubChem Compound
1548943
PubChem Substance
347827793
ChemSpider
1265957
BindingDB
20461
ChEBI
3374
ChEMBL
CHEMBL294199
HET
4DY
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Capsaicin
ATC Codes
M02AB01 — CapsaicinN01BX04 — Capsaicin
AHFS Codes
  • 84:24.04 — Basic Lotions and Liniments
PDB Entries
2n27
FDA label
Download (532 KB)
MSDS
Download (49.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceMigraine Disorders1
0CompletedDiagnosticAmyotrophic Lateral Sclerosis (ALS)1
0RecruitingDiagnosticOculopharyngeal Muscular Dystrophy1
0RecruitingTreatmentAmyotrophic Lateral Sclerosis (ALS)1
1Active Not RecruitingBasic ScienceCluster Headache / Hemicrania Continua / Migraines / Paroxysmal Hemicrania / Short-Lasting Unilateral Neuralgiform Headache With Conjunctival Injection and Tearing / SUNCT / Trigeminal Autonomic Cephalgia1
1CompletedSupportive CarePain1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentHuman Volunteers1
1CompletedTreatmentMorton's neuralgia1
1CompletedTreatmentPain1
1Not Yet RecruitingTreatmentKnee Osteoarthritis (Knee OA)1
1RecruitingTreatmentKnee Osteoarthritis (Knee OA)1
1, 2CompletedDiagnosticCoughing1
1, 2CompletedTreatmentCoughing / Parkinson's Disease (PD)1
1, 2CompletedTreatmentInterstitial Cystitis / Vulvar Diseases1
1, 2CompletedTreatmentPeripheral Nerve Injury (PNI) / Postherpetic Neuralgia1
1, 2CompletedTreatmentPruritus1
1, 2CompletedTreatmentStroke, Ischemic1
1, 2RecruitingBasic ScienceHealthy Volunteers1
1, 2RecruitingTreatmentDiabetes Mellitus (DM) / Diabetes, Autoimmune / Diabetes, Diabetes Mellitus Type 1 / Hypoglycemia1
1, 2RecruitingTreatmentHypertriglyceridemias1
2CompletedTreatmentArthroplasty, Replacement, Knee / Knee Injuries1
2CompletedTreatmentFacial Pain1
2CompletedTreatmentHealthy Volunteers / Tooth Extractions1
2CompletedTreatmentHerpes Zoster / Neurocostal neuralgia / Pain / Peripheral Nervous System Diseases1
2CompletedTreatmentIntrauterine Growth Restriction1
2CompletedTreatmentLateral Epicondylitis1
2CompletedTreatmentMania1
2CompletedTreatmentNeuroma1
2CompletedTreatmentPain / Postherpetic Neuralgia1
2CompletedTreatmentPain / Pulmonary Hypertension (PH)1
2CompletedTreatmentPostherpetic Neuralgia1
2CompletedTreatmentPostoperative pain2
2CompletedTreatmentPulmonary Arterial Hypertension (PAH) / Pulmonary Hypertension (PH)1
2RecruitingTreatmentCyclical Vomiting1
2RecruitingTreatmentNonallergic Irritant Rhinitis1
2RecruitingTreatmentPain, Neuropathic1
2TerminatedBasic ScienceHealthy Volunteers1
2TerminatedTreatmentArthroplasty1
2TerminatedTreatmentRotator Cuff Repair of the Shoulder1
2WithdrawnTreatmentMyofascial Pain Syndrome1
2WithdrawnTreatmentPain, Acute1
2, 3CompletedTreatmentDiabetic Polyneuropathy1
2, 3Not Yet RecruitingTreatmentDyslipidemias / Overweight or Obesity1
2, 3RecruitingTreatmentVestibulodynia1
2, 3Unknown StatusTreatmentPainful Diabetic Neuropathy1
2, 3WithdrawnTreatmentHuman Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) / Immune Reconstitution Inflammatory Syndrome / Immune Reconstitution Syndrome / Tuberculosis1
3CompletedPreventionCoronary Arteriosclerosis1
3CompletedSupportive CareTotal Knee Arthroplasty (Replacement)1
3CompletedTreatmentDiabetic Peripheral Neuropathy (DPN) / Pain1
3CompletedTreatmentDry Eye Syndromes1
3CompletedTreatmentHerpes Zoster / Neurocostal neuralgia / Pain / Peripheral Nervous System Diseases / Shingles2
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Pain / Peripheral Nervous System Diseases1
3CompletedTreatmentPain1
3CompletedTreatmentPain, Acute1
3CompletedTreatmentPainful Diabetic Peripheral Neuropathy (PDPN)1
3RecruitingSupportive CarePain1
3TerminatedTreatmentPersistent Pain After Inguinal Herniotomy1
3TerminatedTreatmentStable Angina (SA)1
3Unknown StatusPreventionCoronary Arteriosclerosis1
4CompletedBasic ScienceHealthy Volunteers1
4CompletedDiagnosticAlopecia Areata (AA)1
4CompletedPreventionPain1
4CompletedSupportive CareKnee Osteoarthritis (Knee OA)1
4CompletedTreatmentHealthy Controls / Idiopathic Rhinitis Patients1
4CompletedTreatmentNon-diabetic Painful Peripheral Polyneuropathy / Peripheral Nerve Injury (PNI) / Postherpetic Neuralgia ( PHN )1
4CompletedTreatmentOr Peripheral Nerve Injury (PNI) / Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN)1
4CompletedTreatmentPostherpetic Neuralgia1
4CompletedTreatmentRhinitis1
4CompletedTreatmentSub-acute Back Pain1
4Not Yet RecruitingTreatmentPain, Neuropathic1
4RecruitingTreatmentChronic Low Back Pain (CLBP)2
4RecruitingTreatmentNon-Allergic Rhinitis1
4TerminatedTreatmentPsoriasis1
4Unknown StatusTreatmentChronic Renal Failure (CRF) / Pain, Neuropathic1
4WithdrawnTreatmentInduction of Uterine contractions / Labour Pain / Pregnancy Loss1
Not AvailableActive Not RecruitingNot AvailableThoracic Pain2
Not AvailableCompletedNot AvailableAcute Gouty Arthritis / Arthritis / Headaches / Migraines / Muscle Spasms / Radicular syndrome / Synovitis / Tendonitis1
Not AvailableCompletedNot AvailableCoughing1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedNot AvailableHealthy Volunteers / Hyperalgesia / Pain / Peripheral Nervous System Diseases1
Not AvailableCompletedNot AvailableMyofascial Pain Syndrome of the Upper Trapezius1
Not AvailableCompletedNot AvailablePeripheral Neuropathic Pain1
Not AvailableCompletedNot AvailablePost-operative Peripheral Neuropathic Pain1
Not AvailableCompletedNot AvailablePrimary Hyperalgesia1
Not AvailableCompletedOtherSepsis1
Not AvailableCompletedTreatmentStings1
Not AvailableEnrolling by InvitationOtherKnee Osteoarthritis (Knee OA)1
Not AvailableNot Yet RecruitingBasic ScienceCapsaicin / Lidocaine / Pain, Neuropathic / Ultaviolet B Light Burn1
Not AvailableRecruitingNot AvailableArteriovenous Fistulae / Pain, Neuropathic1
Not AvailableRecruitingNot AvailableParkinson's Disease (PD)1
Not AvailableRecruitingBasic ScienceDermatology/Skin - Other / Pain / Pain, Neuropathic / Pruritus1
Not AvailableRecruitingBasic ScienceFibromyalgia / Pain1
Not AvailableRecruitingBasic SciencePain1
Not AvailableRecruitingOtherElderly Women / Sarcopenia1
Not AvailableRecruitingPreventionMorbid Obesity D0097651
Not AvailableRecruitingTreatmentPain, Neuropathic / Spinal Cord Injuries (SCI)1
Not AvailableUnknown StatusNot AvailableLower Limb Amputation / Pain, Neuropathic1
Not AvailableUnknown StatusTreatmentNeck Pain Chronic1
Not AvailableUnknown StatusTreatmentPain Relief1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
PatchTopical.025 g/100g
PatchTopical4 g/100g
PatchTopical.228 mg/99.13mg
DiscTopical
GelTopical0.05 %
LiquidTopical0.025 %
GelTopical.06375 g/255g
GelTopical.02825 g/113g
LiquidTopical.15 g/100mL
CreamTopical.25 mg/mL
PlasterTopical70 mg/1
OilPercutaneous; Topical; Transdermal
CreamTopical.05925 g/237mL
CreamTopical.25 mg/g
LotionTopical0.025 %
CreamTopical1 mg/g
CreamTopical0.075 %
CreamTopical0.025 %
LiquidTopical1.5 mg/mL
PatchTopical.702 mg/1
CreamTopical0.05 %
KitOral; Topical
CreamTopical.001 g/g
LiquidTopical.0015 g/mL
CreamTopical.00035 g/g
GelTopical
CreamTopical.025 %
CreamTopical.35 mg/g
OintmentTopical.25 g/100mL
PatchTopical249 mg/1
LiquidTopical.025 g/100g
CreamOral75 mg/g
PatchTopical.025 g/g
LotionTopical
CreamTopical.27 mg/g
CreamTopical.02125 g/85g
GelTopical.01425 g/57g
LinimentTopical
GelTopical.25 mg/g
CreamTopical.75 mg/mL
CreamTopical.35 mg/mL
CreamTopical.17 g/100g
CreamTopical.1 g/100g
LiquidTopical150 mg/100000mg
LiquidTopical
PatchTopical1.2 mg/1000mg
GelTopical.5 mL/90mL
GelTopical1.5 mL/240mL
CreamTopical.875 mg/3.5g
CreamTopical.0295 g/118mL
CreamTopical.0375 g/50g
OintmentTopical
PatchTopical
CreamTopical.1 g/10g
CreamTopical.0265 g/106g
CreamTopical.025 ug/mL
CreamTopical2.5 mg/g
GelTopical.02125 g/85g
SprayTopical.00025 g/mL
SolutionTopical2.5 mg/mL
CreamTopical
PatchTopical.025 mg/100mg
CreamTopical.02825 g/113g
GelTopical.0295 g/118mL
Kit
PatchCutaneous179 mg
OintmentTopical.05 g/100g
SolutionTopical.25 mg/mL
LotionTopical.025 mL/100mL
CreamTopical.025 g/100g
CreamTopical3 g/100g
GelTopical.06275 g/251mL
Solution / dropsTopical
CreamTopical.025 mg/.001g
GelTopical156.25 ng/mL
PatchTransdermal
PlasterTransdermal
SolutionTopical
PatchTopical.6 mg/1
OilTopical.075 g/50g
CreamTopical.07 g/100g
PatchTopical.25 mg/1
PatchTopical25 mg/1
PlasterTopical
CreamTopical.75 mg/g
Kit
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6239180No1996-11-062016-11-06Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)65MSDS
boiling point (°C)210-220MSDS
water solubilityInsoluble in cold waterMSDS
Predicted Properties
PropertyValueSource
Water Solubility0.00841 mg/mLALOGPS
logP3.8ALOGPS
logP3.75ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)9.93ChemAxon
pKa (Strongest Basic)-0.52ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area58.56 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity90.32 m3·mol-1ChemAxon
Polarizability36.32 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-014i-0901000000-adba1bb6f254087febe8
LC-MS/MS Spectrum - LC-ESI-ITTOF , negativeLC-MS/MSsplash10-014i-0900000000-5be0e66854b20d7a5a03
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-014i-0900000000-4337ff26dcbd2a77725e
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-014i-0900000000-c94a246143850aa73e44
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-014r-0950000000-3d145ef428e054b3e535
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-014r-0950000000-c3ca097a6480ab798ff3
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0900000000-4e8f98d1f848f30117d7
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-000i-0900000000-58fab2fdd15893ea71e7
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-000i-0900000000-296a0cb1555da4f1ccd7
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-03di-0209000000-a91e6403d5a0c0b67c2e
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-03di-0209000000-dd0879d3f4f3a8b022c3
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-014i-0149000000-d6a9f6e70ae7cd7aec38
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-014i-0149000000-6fcf63c3bf44a4efc5bd
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-06sl-0075690000-b562b766019cc7cbd98f
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-01x3-0094560000-f354077f4cd51e45b945
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-004i-0002900000-ce1ea9819252343543cd
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-004i-0002911000-6c37470f794c89a66410
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-000i-0900000000-00619747b8012ce6aa64
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-000i-0900000000-3ca73f5212a7643b45d2
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-03dr-0956000000-d0dbf319e1bb02a1aa21
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-03dr-0958000000-a53fd50bc48a51d95c1c
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-004i-0096000000-265377cd56468981c3a3
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-004i-0096000000-da1cc255516c9c58c6f6

Taxonomy

Description
This compound belongs to the class of organic compounds known as methoxyphenols. These are compounds containing a methoxy group attached to the benzene ring of a phenol moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenols
Sub Class
Methoxyphenols
Direct Parent
Methoxyphenols
Alternative Parents
Phenoxy compounds / Methoxybenzenes / Anisoles / Alkyl aryl ethers / 1-hydroxy-2-unsubstituted benzenoids / N-acyl amines / Secondary carboxylic acid amides / Organopnictogen compounds / Organonitrogen compounds / Organic oxides
show 2 more
Substituents
Methoxyphenol / Phenoxy compound / Anisole / Methoxybenzene / Phenol ether / Alkyl aryl ether / 1-hydroxy-2-unsubstituted benzenoid / Monocyclic benzene moiety / Fatty acyl / Fatty amide
show 14 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
capsaicinoid (CHEBI:3374) / Capsaicinoids and derivatives (C06866)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Transmembrane signaling receptor activity
Specific Function
Ligand-activated non-selective calcium permeant cation channel involved in detection of noxious chemical and thermal stimuli. Seems to mediate proton influx and may be involved in intracellular aci...
Gene Name
TRPV1
Uniprot ID
Q8NER1
Uniprot Name
Transient receptor potential cation channel subfamily V member 1
Molecular Weight
94955.33 Da
References
  1. Wallace M, Pappagallo M: Qutenza(R): a capsaicin 8% patch for the management of postherpetic neuralgia. Expert Rev Neurother. 2011 Jan;11(1):15-27. doi: 10.1586/ern.10.182. [PubMed:21158551]
  2. Anand P, Bley K: Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth. 2011 Oct;107(4):490-502. doi: 10.1093/bja/aer260. Epub 2011 Aug 17. [PubMed:21852280]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Acts as a mediator of transcriptional repression by nuclear hormone receptors via recruitment of histone deacetylases (By similarity). Functions as an estrogen receptor (ER)-selective coregulator that potentiates the inhibitory activities of antiestrogens and represses the activity of estrogens. Competes with NCOA1 for modulation of ER transcriptional activity. Probably involved in regulating mitochondrial respiration activity and in aging.
Specific Function
Amide binding
Gene Name
PHB2
Uniprot ID
Q99623
Uniprot Name
Prohibitin-2
Molecular Weight
33296.06 Da
References
  1. Kuramori C, Azuma M, Kume K, Kaneko Y, Inoue A, Yamaguchi Y, Kabe Y, Hosoya T, Kizaki M, Suematsu M, Handa H: Capsaicin binds to prohibitin 2 and displaces it from the mitochondria to the nucleus. Biochem Biophys Res Commun. 2009 Feb 6;379(2):519-25. doi: 10.1016/j.bbrc.2008.12.103. Epub 2008 Dec 29. [PubMed:19116139]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Takanohashi T, Isaka M, Ubukata K, Mihara R, Bernard BK: Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S. doi: 10.1177/1091581809360282. [PubMed:20388821]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Park JS, Choi MA, Kim BS, Han IS, Kurata T, Yu R: Capsaicin protects against ethanol-induced oxidative injury in the gastric mucosa of rats. Life Sci. 2000 Nov 10;67(25):3087-93. [PubMed:11125845]
  2. Hwang JT, Lee YK, Shin JI, Park OJ: Anti-inflammatory and anticarcinogenic effect of genistein alone or in combination with capsaicin in TPA-treated rat mammary glands or mammary cancer cell line. Ann N Y Acad Sci. 2009 Aug;1171:415-20. doi: 10.1111/j.1749-6632.2009.04696.x. [PubMed:19723084]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Peroxidase activity
Specific Function
Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production o...
Gene Name
MPO
Uniprot ID
P05164
Uniprot Name
Myeloperoxidase
Molecular Weight
83867.71 Da
References
  1. Ikeura T, Kataoka Y, Wakabayashi T, Mori T, Takamori Y, Takamido S, Okazaki K, Yamada H: Effects of sensory denervation by neonatal capsaicin administration on experimental pancreatitis induced by dibutyltin dichloride. Med Mol Morphol. 2007 Sep;40(3):141-9. Epub 2007 Sep 18. [PubMed:17874046]
  2. Park JS, Choi MA, Kim BS, Han IS, Kurata T, Yu R: Capsaicin protects against ethanol-induced oxidative injury in the gastric mucosa of rats. Life Sci. 2000 Nov 10;67(25):3087-93. [PubMed:11125845]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Babbar S, Chanda S, Bley K: Inhibition and induction of human cytochrome P450 enzymes in vitro by capsaicin. Xenobiotica. 2010 Dec;40(12):807-16. doi: 10.3109/00498254.2010.520044. Epub 2010 Sep 23. [PubMed:20863199]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Surh YJ, Lee SS: Capsaicin, a double-edged sword: toxicity, metabolism, and chemopreventive potential. Life Sci. 1995;56(22):1845-55. [PubMed:7746093]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. Dina OA, Khasar SG, Alessandri-Haber N, Bogen O, Chen X, Green PG, Reichling DB, Messing RO, Levine JD: Neurotoxic catecholamine metabolite in nociceptors contributes to painful peripheral neuropathy. Eur J Neurosci. 2008 Sep;28(6):1180-90. doi: 10.1111/j.1460-9568.2008.06425.x. Epub 2008 Sep 9. [PubMed:18783367]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
L-ascorbic acid binding
Specific Function
Conversion of dopamine to noradrenaline.
Gene Name
DBH
Uniprot ID
P09172
Uniprot Name
Dopamine beta-hydroxylase
Molecular Weight
69064.45 Da
References
  1. Dina OA, Khasar SG, Alessandri-Haber N, Bogen O, Chen X, Green PG, Reichling DB, Messing RO, Levine JD: Neurotoxic catecholamine metabolite in nociceptors contributes to painful peripheral neuropathy. Eur J Neurosci. 2008 Sep;28(6):1180-90. doi: 10.1111/j.1460-9568.2008.06425.x. Epub 2008 Sep 9. [PubMed:18783367]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Manganese ion binding
Specific Function
This enzyme has 2 functions: it catalyzes the production of glutamine and 4-aminobutanoate (gamma-aminobutyric acid, GABA), the latter in a pyridoxal phosphate-independent manner (By similarity). E...
Gene Name
GLUL
Uniprot ID
P15104
Uniprot Name
Glutamine synthetase
Molecular Weight
42064.15 Da
References
  1. Okere CO, Waterhouse BD: Capsaicin increases GFAP and glutamine synthetase immunoreactivity in rat arcuate nucleus and median eminence. Neuroreport. 2004 Feb 9;15(2):255-8. [PubMed:15076747]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Orhan I, Naz Q, Kartal M, Tosun F, Sener B, Choudhary MI: In vitro anticholinesterase activity of various alkaloids. Z Naturforsch C. 2007 Sep-Oct;62(9-10):684-8. [PubMed:18069241]

Drug created on September 14, 2010 10:21 / Updated on August 15, 2018 09:54